On July 2, 2022 EpiAxis Therapeutics, reported the results of its pioneering clinical trial EPI-PRIMED published in leading cancer journal Frontiers of Oncology and company executives returning to face-to-face biotech conferences in the United States (Press release, EpiAxis Therapeutics, JUL 2, 2022, View Source;utm_medium=rss&utm_campaign=epiaxis-highlights-june-2022 [SID1234616449]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
EPI-PRIMED is the first time that an epigenetic inhibitor has been used in combination with chemotherapy to treat metastatic cancer. The purpose of the EPI-PRIMED study was to investigate the safety of the combination, nab-paclitaxel and an irreversible LSD1 inhibitor, in patients with metastatic breast cancer (mBC). Women with inoperable or metastatic breast cancer from three Australian facilities: Canberra Region Cancer Centre, Southern Medical Day Care Centre and Liverpool Hospital participated in the study.
CEO Jeremy Chrisp said: "The publication of this study is the culmination of several years’ work and the results are important for both patients and the company, as we have demonstrated that nuclear inhibition of LSD1 is possible and results in cell reprogramming. This indicates that we are on the right track to progress our novel first in class candidates to a new clinical trial. We would like to thank the staff and patients of the three sites that participated, as well as EpiAxis Therapeutics founding scientist Professor Sudha Rao. We look forward to sharing the immune data from the study in the near future."
The findings of the EPI-PRIMED study give EpiAxis a solid foundation for its next clinical trial using its novel peptide inhibitors. The company is currently working with The Sage Group to raise US$12million to advance a candidate into an IND enabled program.
EpiAxis Chairman Dr David Fuller attended the ASCO (Free ASCO Whitepaper) 2022 Annual Meeting in Chicago from June 3-7, 2022. The American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) is the world’s premier oncology gathering. It was held in Chicago for the first time since 2019, bringing the largest crowd of cancer care leaders together since the start of the pandemic.
The 2022 ASCO (Free ASCO Whitepaper) Annual Meeting Program offered presentations on the latest research in cancer care and extensive networking opportunities. This year’s program featured over 200 sessions complementing the meeting’s theme: Advancing Equitable Cancer Care Through Innovation.
More than 36,000 people registered for the conference, making it an excellent networking opportunity.
"It was great to see ASCO (Free ASCO Whitepaper) return to Chicago and have the opportunity to interact with with industry colleagues again after the COVID-19 pandemic," Dr Fuller (above, with Wayne Pambianchi from The Sage Group) said. "Each year, the ASCO (Free ASCO Whitepaper) conference brings together oncologists from all around the globe and is attended by medical, educational and industrial stakeholders involved in the field of oncology worldwide. It was an invaluable opportunity to share EpiAxis’ epigenetic advances with a highly engaged audience."
EpiAxis CEO Dr Jeremy Chrisp attended the BIO International Convention with The Sage Group from 13-16 June 2022 at San Diego Convention Center.
The convention featured more than 100 interactive sessions across four days, covering a variety of therapeutic areas, business development, digital health, patient advocacy and next generation biotherapeutics.
"BIO International was an exciting opportunity to meet with investors as we seek to advance our pioneering epigenetic program into the clinic," Dr Chrisp said.
"We are looking to continue our discussions with potential pharma partners who are receptive to our novel first-in-class oncology therapeutics. Epigenetics is an emerging and active therapeutic area and offers the prospect of a less toxic cancer treatment by re-programming both cancer and immune cells for superior outcomes.
"EpiAxis is now moving into the next phase of development and is seeking to raise US $12million (tranched) to take us from lead candidate selection through IND filing and an initial Phase 1/2 dose escalation expansion study."